Anthea on behalf of Dennis Ding's questions to Rhythm Pharmaceuticals Inc (RYTM) leadership • Q4 2024
Question
Anthea, on behalf of Dennis Ding, asked about GLP-1 use at baseline in the Phase III HO trial and if there is any efficacy or enrollment read-through from the setmelanotide trial to the bivamelagon trial.
Answer
CEO David Meeker clarified that about 25% of patients in the Phase III HO trial had prior GLP-1 use but had to be on a stable regimen, and new weight loss drugs were not permitted. He stated that the bivamelagon Phase II trial is blinded and enrolls an older population (12+), so there is no direct read-through on efficacy at this time.